Nasdaq-listed Biotech ZLAB Passes the Hearing for Hong Kong IPO
ZLAB, the Nasdaq-listed China concept biotech pharmaceutical, passed the hearing by the Hong Kong Stock Exchange Committee and looking for a forthcoming IPO event. The company went public on Nasdaq in September 2017.
Based in China, ZLAB is innovative biotechnology with operational offices worldwide. The company aims to provide innovative drugs for worldwide patients with cancer, immunology diseases and infectious diseases.